[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360373-105":59,"doc-detail-360373-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","targeting-tumor-specific-t-cells-with-lag3-directed-interleukin-2-prevents-t-cell-exhaustion-and-reinvigorates-antitumor-immunity","Targeting tumor-specific T cells with LAG3-directed interleukin-2 prevents T-cell exhaustion and reinvigorates antitumor immunity","","LAG3 is identified as an inhibitory receptor enriched on exhausted T cells in the tumor microenvironment, where it drives impaired antitumor immunity. In a colon cancer model, LAG3+CD8+ tumor-infiltrating lymphocytes show defective IL2 signaling. A precision fusion protein, LAG3-LaIL2, selectively delivers low-affinity IL2 to LAG3+CD8+ TILs, expanding pre-exhausted states, reprogramming exhaustion toward an intermediate effector phenotype, and preventing terminal exhaustion, resulting in tumor regression and prolonged survival in mice. Mechanistically, LAG3-LaIL2 restores IL2R-JAK3-STAT5 signaling by upregulating CD122, enhances effector and memory formation in draining lymph nodes, and enables systemic immunity against distal tumors while restricting IL2 exposure to nontarget cells. ",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-tumor-specific-t-cells-with-lag3-directed-interleukin-2-prevents-t-cell-exhaustion-and-reinvigorates-antitumor-immunity/360373/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-tumor-specific-t-cells-with-lag3-directed-interleukin-2-prevents-t-cell-exhaustion-and-reinvigorates-antitumor-immunity/360373.png","ImageObject",300,407,{"name":92,"@type":93},"McQueen","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is LAG3 considered a promising target for T-cell exhaustion in tumors?","Question",{"text":113,"@type":114},"LAG3 is enriched on exhausted and dysfunctional tumor-infiltrating CD8+ T cells and acts as a key driver of T-cell exhaustion, forming a resilient immunosuppressive axis in the tumor microenvironment.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What is LAG3-LaIL2 and what problem does it address?",{"text":118,"@type":114},"LAG3-LaIL2 is a fusion protein engineered to selectively deliver IL2 to LAG3+CD8+ tumor-infiltrating lymphocytes, aiming to restore IL2 signaling and reverse dysfunction without broadly activating nontarget cells.",{"name":120,"@type":111,"acceptedAnswer":121},"How does LAG3-LaIL2 reinvigorate antitumor immunity mechanistically?",{"text":122,"@type":114},"It restores IL2R-JAK3-STAT5 signaling by upregulating the high-affinity IL2 receptor subunit CD122, reprogramming the exhaustion trajectory toward an intermediate effector state and preventing terminal exhaustion.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},360373,1790386217,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":36,"preview_page_count":19,"preview_urls":146},5909890329169,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Signal Transduction [and Targeted Therapy](and Targeted Therapy www.nature.com/sigtrans)[ www.nature.com/sigtrans](and Targeted Therapy www.nature.com/sigtrans)  \nARTICLE OPEN  \nTargeting tumor-speciﬁc T cells with LAG3-directed interleukin-2 prevents T-cell exhaustion and reinvigoratesantitumor immunity  \nXiaohong Yu1, Huiping Liao1, Jiaoyun Lv 1, Yu Sun1, Ruiqi Zhang1, Yiwei Chen1, Yifan Lin1, Lulu Liu 1, Shijie Li1,2,3, Hui Tang4, Panpan Jia 1,5, Bin Shao5, Zaopeng Yang 1, Yang-Xin Fu 1,2,3 ✉ and Zhenhua Ren 1,5 ✉  \n\n|  | LAG3 is a critical inhibitory receptor that is highly enriched on exhausted T cells within the tumor microenvironment (TME), where it acts as a key driver of T-cell exhaustion—an archetypal barrier to robust antitumor immunity. In a colon cancer model, LAG3+CD8+ tumorinﬁltrating lymphocytes (TILs) constitute the predominant type of tumor-speciﬁc T cells but exhibit defective IL2 signaling. To address whether exogenous IL2 replenishment unpins their dysfunction, we engineered LAG3-LaIL2 (low-afﬁnity IL2), a fusion protein that selectively delivers IL2 to LAG3+CD8+ TILs. LAG3-LaIL2 expanded pre-exhausted tumor-speciﬁc CD8+ T cells, reprogrammed their exhaustion trajectory toward an intermediate effector state, and prevented terminal exhaustion, leading to tumor regression and prolonged survival in mice. Mechanistically, LAG3-LaIL2 restored IL2R-JAK3-STAT5 signaling by upregulating the high-afﬁnity IL2 receptor subunit CD122, thereby restoring TIL functionality. Furthermore, LAG3-LaIL2 ampliﬁed tumor-speciﬁc effector and memory T cells in draining lymph nodes, enabling systemic antitumor immunity against distal tumors and preventing tumor recurrence. Collectively, our ﬁndings identify LAG3-LaIL2 as a precision immunotherapy that speciﬁcally targets exhausted TILs while restricting IL2 exposure to nontarget cells, thereby enhancing both the efﬁcacy and safety of this approach. This approach provides a translatable strategy to |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| overcome T-cell exhaustion in solid tumors and represents a promising avenue to improve clinical outcomes in cancer patients. |  |  |\n|  | Signal Transduction and Targeted Therapy (2026)11:207 ; [https://doi.org/10.1038/s41392-026-02667-8](https://doi.org/10.1038/s41392-026-02667-8) |  |\n|  |  |  |\n\nINTRODUCTION  \nTumor-reactive CD8+ T cells have the inherent capacity to eradicate cancer cells, as evidenced by the clinical success of immune checkpoint blockade (ICB) therapies targeting pathways such as the PD-1/PD-L1 pathway.1 However, tumors frequently evade immune elimination via compensatory upregulation of alternative inhibitory receptors, including LAG3 and TIM3, which drive T-cell dysfunction and exhaustion.2–4 Lymphocyte activation gene-3 (LAG3; CD223), a coinhibitory receptor enriched in exhausted and dysfunctional tumor-inﬁltrating CD8+ T cells, synergizes with PD-1 to suppress T-cell receptor (TCR) signaling and cytokine production, thereby establishing a resilient immunosuppressive axis in the TME.3,5–7  \nNotably, dual anti-PD-1/anti-LAG3 blockade therapy (Opdualag®) was approved by the FDA in 2022 for unresectable or metastatic melanoma, demonstrating that LAG3 inhibition can enhance antitumor immunity when combined with PD-1 blockade.8–10 This regulatory milestone demonstrates the therapeutic potential of cotargeting nonredundant inhibitory pathways, addressing the immune evasion mechanisms that often constrain responses to single-agent checkpoint therapies. While dual PD-1/ LAG3 blockade has shown promise for overcoming resistance to single-agent ICBs, many patients still fail to respond because of  \nthe epigenetic and functional heterogeneity of exhausted T-cell states.11 This highlights the urgent need for novel immunomodulatory strategies to dismantle treatment resistance mechanisms. Exhausted CD8+ T cells within the TME exhib","cbCaibgBYEHa5HiN","https://ap.wps.com/l/cbCaibgBYEHa5HiN","pdf",5990369,16,"English","# Introduction\n## Targeting inhibitory pathways in exhausted T cells\n## Dual blockade and limitations\n## Pre-exhausted LAG3+ CD8+ T-cell therapeutic window\n## Challenges and rationale for IL2 delivery","[{\"question\":\"Why is LAG3 considered a promising target for T-cell exhaustion in tumors?\",\"answer\":\"LAG3 is enriched on exhausted and dysfunctional tumor-infiltrating CD8+ T cells and acts as a key driver of T-cell exhaustion, forming a resilient immunosuppressive axis in the tumor microenvironment.\"},{\"question\":\"What is LAG3-LaIL2 and what problem does it address?\",\"answer\":\"LAG3-LaIL2 is a fusion protein engineered to selectively deliver IL2 to LAG3+CD8+ tumor-infiltrating lymphocytes, aiming to restore IL2 signaling and reverse dysfunction without broadly activating nontarget cells.\"},{\"question\":\"How does LAG3-LaIL2 reinvigorate antitumor immunity mechanistically?\",\"answer\":\"It restores IL2R-JAK3-STAT5 signaling by upregulating the high-affinity IL2 receptor subunit CD122, reprogramming the exhaustion trajectory toward an intermediate effector state and preventing terminal exhaustion.\"}]","Targeting tumor-specific T cells with LAG3-directed interleukin-2 prevents T-cell exhaustion and reinvigorates antitumor immunity | PDF",1790139837,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fdcd63b5fd80432c5165ee57adf09df5.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/019ad383138a234c67f5a31540120fda.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/459636bde44cb1fbe289c5e9ebfdf5b6.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9dd8af0ffab05ad33efeaf1fdd49ea9d.webp",980,1301]